Better supplements do not always begin with discovering better ingredients. Nutritional science has identified thousands of bioactive compounds capable of influencing human physiology. Some are produced naturally by the body, others are found in rare plants, marine organisms or foods that have formed part of the human diet for centuries. Every year, new studies expand our understanding of how these molecules interact with biological processes involved in sleep, metabolism, inflammation, cognition, healthy ageing and many other aspects of health.

Given the growing number of bioactives supported by experimental and clinical research, it would be reasonable to assume that the greatest challenge facing nutritional science is the discovery of the next important ingredient. Our research gradually led us to a different conclusion.

For many bioactives, the limiting factor is no longer understanding what the molecule does. It is understanding how to formulate that molecule so that its biological properties have the greatest opportunity to be expressed after oral administration.

That distinction is easily overlooked. When two supplements contain the same ingredient at the same dose, they are often assumed to be functionally equivalent. Chemically they may be. Physically they are not necessarily the same.

Every oral formulation begins a sequence of events that takes place before absorption is even possible. The bioactive must remain stable throughout manufacture and storage. After ingestion it must disperse within gastrointestinal fluids, remain available as it passes through the small intestine and encounter the absorptive surface under conditions that favour uptake. Each of these steps is governed not only by the properties of the bioactive itself, but also by the way it has been formulated.

This is where formulation science becomes important.

• Different bioactives present different formulation challenges.
• Lipophilic compounds have little affinity for the aqueous environment of the gastrointestinal tract.
• Oxidation-sensitive molecules may gradually lose activity during storage.
• Oil-based ingredients often require specialised approaches before they can be incorporated into conventional capsules or tablets.
• Other compounds dissolve rapidly but remain available for absorption only briefly before progressing further through the digestive tract.

These are physical problems. They occur before receptors, signalling pathways or metabolic processes become relevant.

For us, that observation changed the direction of our research. Instead of concentrating exclusively on identifying additional bioactives, we began investigating whether some of these formulation barriers could be addressed without altering the chemistry of the molecule itself. That work ultimately became Dual Vector™.

Dual Vector™ is a formulation platform and not a bioactive ingredient on its own. It was developed to address several of the physical limitations encountered by lipophilic and oxidation-sensitive compounds before absorption takes place.

The platform distributes bioactives throughout a hydrophilic carrier system that disperses readily after ingestion, increasing the surface over which the bioactive becomes available within the gastrointestinal tract. As the carrier gradually dissolves, additional bioactive continues to become available further along the small intestine instead of being released at a single location. The same platform also converts oil-based ingredients into stable free-flowing powders while helping protect oxidation-sensitive compounds during manufacture and storage.

Importantly, none of these mechanisms change the biological properties of the molecule. They address the formulation surrounding the molecule, but its functions

remain exactly the same.

We always aim to reduce the physical obstacles for the bioactive molecule to perform its natural function without changing the molecule through any structural or functional modifications.

This principle continues to guide every formulation developed at Fortivion Labs. We begin by identifying bioactives supported by sound scientific evidence and a clear

physiological rationale. We then examine whether the formulation itself may be limiting their performance after oral administration. Only when a genuine formulation problem exists do we consider whether Dual Vector™ offers an appropriate solution.

For us, formulation is not the final manufacturing step.

It is part of the science.